AZD8965 compared with placebo in adults with idiopathic pulmonary fibrosis
Tests 3 doses of AZD8965 against placebo in adults with idiopathic pulmonary fibrosis.
Plain-language title generated from the registry record
Registry title: A Phase IIb Study to Evaluate AZD8965 in Participants With IPF.
Key facts
- Where
- Angers, Brest, Bron, Montpellier, Nice, Paris, Rennes, and Tours, FranceSee the 8 sites
- Phase
- Phase 2
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 40 or older with idiopathic pulmonary fibrosis (IPF), with or without current antifibrotic treatment.
- Age
- 40 years or older
- Sex
- All sexes can join.
- Disease stage
- IPF diagnosis. FVC at least 45% predicted of normal. DLCO corrected for hemoglobin at least 25% predicted of normal.
- Earlier treatment
- People can join if they take approved antifibrotic treatment at a stable dose, or if they do not take standard treatment for IPF.
Main reasons for not taking part
- Lung disease other than IPF
- More emphysema than fibrotic change on chest scan (HRCT)
- Acute worsening (exacerbation) of IPF
- Lower respiratory tract infection needing treatment
- History of organ transplant or likely to receive a lung transplant
Read by machine on 12 November 2026.
Where in France
- AngersHospital not named in the registryNot yet recruiting
- BrestHospital not named in the registryTaking people
- BronHospital not named in the registryTaking people
- MontpellierHospital not named in the registryNot yet recruiting
- NiceHospital not named in the registryTaking people
- ParisHospital not named in the registryNot yet recruiting
- RennesHospital not named in the registryNot yet recruiting
- ToursHospital not named in the registryTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- AstraZeneca
- Trial code
- NCT07652658
- Record updated
- 29 October 2026
- Original description
This Phase IIb study aims to evaluate the efficacy, safety, and tolerability of 3 doses of AZD8965 treatment compared to placebo in participants with IPF, including those on antifibrotic therapy (nintedanib, pirfenidone, nerandomilast), either alone or in combination, or in those not on antifibrotic therapy.Read full original descriptionShow less
A Phase IIb Study to Evaluate the Efficacy, Safety, and Tolerability of AZD8965 in Participants With Idiopathic Pulmonary Fibrosis (IPF) (ARGiNAUT)
This Phase IIb study aims to evaluate the efficacy, safety, and tolerability of 3 doses of AZD8965 treatment compared to placebo in participants with IPF, including those on antifibrotic therapy (nintedanib, pirfenidone, nerandomilast), either alone or in combination, or in those not on antifibrotic therapy.
Inclusion: Age ≥ 40 years; IPF diagnosis; Participants with IPF receiving locally approved antifibrotic therapies at a stable dose, or participants with IPF not receiving local standard of care; FVC ≥ 45% predicted of normal; DLCO corrected for hemoglobin ≥ 25% predicted of normal.
Exclusion: Lower respiratory tract infection requiring treatment; Acute coronary syndrome/acute myocardial infarction, unstable angina ± coronary intervention with Percutaneous Coronary Intervention, or Coronary Artery Bypass Grafting; Heart failure; History of organ transplantation or is likely to receive lung transplantation; ILD other than IPF; The extent of emphysema is greater than the extent of fibrotic changes on chest HRCT scan; Acute exacerbation of IPF.